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INTRODUCTION: Nanosized liposomes are among 
nanotechnological delivery methods for 
chemotherapeutic drugs in the treatment of cancer. This 
technique can potentially overcome many common 
pharmacologic problems, such as those involving 
solubility, pharmacokinetics, in vivo stability and 
toxicity. Liposomes are closed spherical vesicles 
consisting of a lipid bilayer that encapsulates an 
aqueous phase in which hydrophilic drugs can be 
stored, while water insoluble compounds can be 
incorporated in the hydrophobic region of the lipid 
bilayer [1,2]. In this work, a potential antitumoral 
fluorescent indole derivative 1, previously synthesized 
by us [3], has been encapsulated in nanoliposomes of 
DPPC (dipalmitoyl phosphatidylcholine), egg-yolk 
phosphatidylcholine (Egg-PC) and dioctadecyl-
dimethylammonium bromide (DODAB).   
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Methyl 6-methoxy-3-(4-
methoxyphenyl)-1H-
indole-2-carboxylate 
 
METHODS: Nanoliposomes were prepared by 
injection of an ethanolic solution of the lipid in an 
aqueous media under vigorous stirring, above the lipid 
melting transition temperature. Mean liposome size was 
measured by dynamic light scattering (DLS). The 
encapsulation of compound 1 in the nanoliposomes was 
assessed by fluorescence resonance energy transfer 
(FRET) between the fluorescent compound 1 and the 
fluorescent labelled phosphatidylethanolamine NBD-
PE, included in the liposome formulation (with NBD-
PE/lipid ratio of 1:250).  
RESULTS: The nanoliposome hydrodynamic 
diameters, obtained by DLS, are 87 ± 11 nm for DPPC, 
51 ± 2 nm for Egg-PC and 268 ± 37 nm for DODAB. 
All samples are monodisperse. 
Antitumoral evaluation: The effect of compound 1 on 
the in vitro growth of three human tumor cell lines, 
breast adenocarcinoma (MCF-7), non-small cell lung 
cancer (NCI-H460) and a melanoma cell line (A375-
C5), was evaluated after a continuous exposure of 48 h 
(Table 1).  
 
 
Table 1. Values of compound 1 concentration needed 
for 50% of cell growth inhibition (GI50) 
 GI50 (μM) 
MCF-7 NCI-H460 A375-C5 
1 0.37 ± 0.02 0.33 ± 0.03 0.25 ± 0.02 
 
Fluorescence measurements showed the possibility of 
FRET between the electronic excited compound (acting 
as donor) and the labelled lipid NBD-PE (with NBD 
acting as energy acceptor). In Figure 1 it is possible to 
observe a strong NBD emission upon excitation of 
compound 1 incorporated in nanoliposomes.  
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Fig. 1: Fluorescence spectra of compound 1 in Egg-PC 
liposomes labelled with NBD-PE and labelled Egg-PC 
liposomes alone (λexc=325 nm). 
DISCUSSION & CONCLUSIONS: Compound 1 
shows excellent antitumoral properties, exhibiting very 
low GI50 values in the three tumor cell lines. FRET 
assays indicate that compound 1 molecules and the 
NBD-labelled lipids are in close proximity in 
nanoliposomes. These results are important for drug 
delivery purposes, considering the antitumoral 
properties of compound 1. 
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